Performance of the Sensititre YeastOne assay compared with EUCAST E.Def 9.4 against Fusarium clinical isolates: focus on voriconazole and amphotericin B
Abstract
Abstract Objectives Despite the global emergence of Fusarium infections, data validating commercial antifungal susceptibility testing against these moulds remain scarce. We evaluated the performance and optimal reading time of the Sensititre YeastOne (SYO) assay against Fusarium clinical isolates compared with the EUCAST reference method. Methods This two-centre study (2011–2023) analysed 123 Fusarium isolates identified via two-step molecular sequencing. In vitro susceptibilities to voriconazole and amphotericin B were evaluated using SYO (24 h and 48 h readouts) versus the EUCAST E.Def 9.4 broth microdilution reference method (48 h readout). Essential agreement (EA) was defined as a ±2 log2 dilution difference; >90% was acceptable. Results Fusarium solani species complex (FSSC) dominated the cohort (85.3%), predominantly F. keratoplasticum and F. pseudensiforme. EUCAST testing revealed high MIC50/MIC90 values of voriconazole (>16/>16 mg/L) and amphotericin B (2/16 mg/L). While 65% (80/123) of isolates displayed positivity by SYO at 24 h, median spectrophotometric growth was significantly greater at 48 h than at 24 h [0.37 (IQR 0.315–0.403) versus 0.18 (0.151–0.206)]. At 48 h, EA approached acceptability for voriconazole (92.7%) and amphotericin B (89.4%). Voriconazole categorical agreement (CA) among FSSC was 88.6% and reached 96.9% for F. pseudensiforme. For amphotericin B, SYO MICs clustered around 4–8 mg/L, yielding 100% very major error for F. keratoplasticum and F.…
How strong is the evidence?
Evidence Hub reads this as a cohort study. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.